- Event

Asceneuron presents the novel M1-targeting compound ASN-51

Asceneuron presents the novel M1-targeting compound ASN-51 at the 11th International Conference on Alzheimer's and Parkinson's disease held 6-10 March 2013 in Florence, Italy.

- Press releases

Merck Serono announces the creation of Asceneuron

Merck Serono announces the creation of Asceneuron, the third Spin-Off company from its entrepreneur Partnership Program. Asceneuron will develop Merck Serono’s research programs in the area of Alzheimer’s disease.